Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Robert H.I. Andtbacka"'
Autor:
Salah-Eddine Bentebibel, Willem W. Overwijk, Montaser Shaheen, Marc Uemura, Courtney W. Hudgens, Marihella James, Ravi Murthy, Gary C. Doolittle, Robert H.I. Andtbacka, Chantale Bernatchez, Michael A. Davies, S. Chunduru, Douglas B. Johnson, Daniel H. Johnson, Igor Puzanov, Patrick Hwu, Shah Rahimian, Cara Haymaker, Adi Diab, Joseph Markowitz, Denái R. Milton, Michael T. Tetzlaff, Sudhir Agrawal, Nashat Gabrail, Houssein Safa
Publikováno v:
Cancer Discov
Many patients with advanced melanoma are resistant to immune checkpoint inhibition. In the ILLUMINATE-204 phase I/II trial, we assessed intratumoral tilsotolimod, an investigational Toll-like receptor 9 agonist, with systemic ipilimumab in patients w
Autor:
Jessica L. Cindass, Thomas E. Wagner, Annelies T. Hickerson, Jeffrey J. Sussman, Alexandra M Adams, Adam C. Berger, Robert C. Chick, Alicia M. Terando, Timothy J. Vreeland, Robert H.I. Andtbacka, Guy T. Clifton, Diane F. Hale, Phillip M. Kemp Bohan, Mark B. Faries, James W. Jakub, George E. Peoples
Publikováno v:
Annals of Surgical Oncology
Background Melanoma therapy has changed dramatically over the last decade with improvements in immunotherapy, yet many patients do not respond to current therapies. This novel vaccine strategy may prime a patient’s immune system against their tumor
Autor:
F. Stephen Hodi, Kevin J. Harrington, Archie N. Tse, David C. Madoff, Jason J. Luke, Andrea Marie Perrone, Lawrence H. Schwartz, Anuradha D. Khilnani, Robert H.I. Andtbacka, Aurélien Marabelle, Gregory V. Goldmacher
Publikováno v:
Journal of Clinical Oncology
3141 Background: The approval of intratumoral (IT) immunotherapy for metastatic melanoma and the active development of numerous novel IT drugs have created a need for standardized evaluation of response to this unique treatment strategy. The Response
Autor:
Lisa K. Jacobs, Erica B. Friedman, Robert Elashoff, Jonathan S. Zager, Douglas S. Reintgen, Mark B. Faries, John F. Thompson, Nicola Mozzillo, He-Jing Wang, Lisa Van Kreuningen, Alessandro Testori, Lauren E. Haydu, Roger F. Uren, Peter D. Beitsch, B. Mark Smithers, Erwin S. Schultz, Vicki L. Schiller, Mark C. Kelley, Stacey L. Stern, Alistair J. Cochran, Eddy C. Hsueh, Doreen M. Agnese, Robert H.I. Andtbacka, Gregory McKinnon, Schlomo Schneebaum, David Elashoff, Tawnya L. Bowles, John M. Kane, Jeffrey J. Sussman, Harald J. Hoekstra
Publikováno v:
Annals of Surgery, 273(4), 814-820. LIPPINCOTT WILLIAMS & WILKINS
Objective To assess whether preoperative ultrasound (US) assessment of regional lymph nodes in patients who present with primary cutaneous melanoma provides accurate staging. Background It has been suggested that preoperative US could avoid the need
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::469570cfbea5ed2918b58254c2192fed
https://research.rug.nl/en/publications/85c67460-56d0-4574-bb17-aa809932c057
https://research.rug.nl/en/publications/85c67460-56d0-4574-bb17-aa809932c057
Autor:
Robert H.I. Andtbacka, Frances A. Collichio, Gerald Downey, Kevin J. Harrington, Howard L. Kaufman, Mark R. Middleton, Katarina Ӧhrling
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, Australia and Switzerland. We report the final planned analysis of OPTiM, a randomized open-label phase III trial in patients with unresectable stage IIIB
Autor:
Tawnya L. Bowles, David A. Wada, Robert H.I. Andtbacka, Marki E. Klapperich, Lisa A. Cannon-Albright, Glen M. Bowen, Sarah Empey, Aaron M. Secrest, Kenneth F. Grossmann, Douglas Grossman, John R. Hyngstrom, James M. Farnham
Publikováno v:
Journal of the American Academy of Dermatology. 79:238-244
BACKGROUND: Survival data are mixed comparing patients with multiple primary melanomas (MPM) to those with single primary melanomas (SPM). OBJECTIVES: We compared MPM versus SPM patient survival using a matching method that avoids potential biases as
Autor:
Céleste Lebbé, Merrick I. Ross, Axel Hauschild, Theodore F. Logan, Robert H.I. Andtbacka, John A. Glaspy, Philip Friedlander, Claus Garbe, Jason Chesney, Omid Hamid, Howard L. Kaufman, Parminder Singh, Jenny J. Kim, Frances A. Collichio, Jennifer Gansert, Mohammed M. Milhem, Lisa Chen, Igor Puzanov
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 17
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our knowledge, this was the first randomized trial to evaluate addition of an oncolyti
Autor:
Mona L. Martin, Chad J Gwaltney, Jonathan S. Zager, E. A. Wachter, Talia Miller, Matthew C. Perez, Robert H.I. Andtbacka, John F. Thompson, Evan S. Weitman, Jo Dalton, David Sarson
Publikováno v:
Melanoma Research
Locally advanced cutaneous melanoma has marked quality-of-life implications; however, the patient experience of symptom management and subsequent impact on quality of life has not been well described. This study aims to address the impact on patients
Publikováno v:
Annals of Plastic Surgery. 80:32-39
BACKGROUND Ear reconstruction with osseointegrated prosthetic implants is a well-established method of reconstruction after resection of skin malignancies on the external ear. There is limited literature reporting technique, outcomes, and patient sat
Autor:
Maris S. Jones, John F. Thompson, Brendon J. Coventry, Tawnya L. Bowles, Doreen M. Agnese, Douglas L. Johnson, Harald J. Hoekstra, Erwin S. Schultz, Eddy C. Hsueh, Stacey L. Stern, Mohammed Kashani-Sabet, Daniel F. Roses, Lisa K. Jacobs, Omgo E. Nieweg, Alessandro Testori, B. Mark Smithers, Jonathan S. Zager, Mark B. Faries, Peter C. Jones, Nicola Mozzillo, Dave S.B. Hoon, Mark C. Kelley, Robert H.I. Andtbacka, Dirk Noyes, David Elashoff, Schlomo Schneebaum
Publikováno v:
Annals of Surgical Oncology, 24(8), 2089-2094. SPRINGER
Background. Although a well-established causative relationship exists between smoking and several epithelial cancers, the association of smoking with metastatic progression in melanoma is not well studied. We hypothesized that smokers would be at inc